Century Therapeutics Updates ATM Program to Enhance Liquidity

Century Therapeutics ( (IPSC) ) has shared an announcement.

On July 10, 2025, Century Therapeutics, Inc. filed a new shelf registration statement that became effective on January 9, 2026, replacing its prior shelf registration and enabling continued access to the capital markets. In connection with this, on March 26, 2026, the company filed a new prospectus supplement for its at-the-market equity offering program, preserving capacity to sell up to $150 million of common stock, of which approximately $131.6 million remained available, underscoring its intent to maintain funding flexibility for future needs.

As of the date of the new prospectus supplement, Century Therapeutics had already sold about $18.4 million of stock under the program through its sales agent, Cowen and Company, LLC, now TD Securities (USA) LLC. The updated filings, including a reaffirmed sales agreement and a legal opinion from Goodwin Procter LLP, solidify the legal and structural framework supporting the company’s ongoing access to incremental equity financing in the public markets.

The most recent analyst rating on (IPSC) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Century Therapeutics stock, see the IPSC Stock Forecast page.

Spark’s Take on IPSC Stock

According to Spark, TipRanks’ AI Analyst, IPSC is a Neutral.

The score is held back mainly by heavy ongoing cash burn and uneven revenue visibility, despite an improved loss profile and a manageable balance sheet. Offsetting this, the stock’s technical setup is strong and recent financing/pipeline progress provides near-term support, while valuation remains constrained by negative earnings and no dividend.

To see Spark’s full report on IPSC stock, click here.

More about Century Therapeutics

Century Therapeutics, Inc. is a biotechnology company focused on developing cell-based therapies, with its operations financed in part through access to public equity markets. The company utilizes shelf registration statements and an at-the-market equity offering program to maintain flexibility in raising capital as needed to support its research, development, and corporate activities.

Average Trading Volume: 1,849,618

Technical Sentiment Signal: Buy

Current Market Cap: $372M

For an in-depth examination of IPSC stock, go to TipRanks’ Overview page.